Drug · DIN 02459620
ZINBRYTA
PREFILLED SYRINGE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since April 30, 2018; first marketed March 30, 2017.
- Drug Identification Number (DIN)
- 02459620
- Company (DIN owner)
- Biogen Canada IncToronto, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Daclizumab L04AC01
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DACLIZUMAB BETA | 150 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 8, 2016: NOC 18736New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “zinbryta”. A notice may cover another product or only some lots: read it to see what it covers.
- ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of EncephalitisMarch 16, 2018 · Biologic or vaccine · Product safety
Other DINs named ZINBRYTA
- DIN 02459639 · Cancelled Pre Market